|Bid||84.46 x 1100|
|Ask||84.51 x 1000|
|Day's Range||83.64 - 85.27|
|52 Week Range||34.04 - 85.27|
|Beta (5Y Monthly)||1.08|
|PE Ratio (TTM)||N/A|
|Earnings Date||Jul 26, 2021 - Jul 30, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||88.00|
MASON, Ohio, July 30, 2021--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that the company will be participating in the upcoming Canaccord 41st Annual Growth Conference.
AtriCure (ATRC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
MASON, Ohio, July 07, 2021--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that it will release second quarter 2021 financial results on Wednesday, August 4, 2021.